Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
ID6130: Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over
ID6170: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A
ID5123: Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
ID3982: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis
ID6405: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
ID5088: Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria
ID4042: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia
ID6298: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
ID6197: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
ID6187: Relugolix for treating hormone-sensitive prostate cancer
ID4025: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
ID5104: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
ID4038: Therapeutics for people with COVID-19
ID1334: Glasdegib with chemotherapy for untreated acute myeloid leukaemia
ID2710: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375)
ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly
ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma
ID1631: Risdiplam for treating spinal muscular atrophy in children and adults
ID1564: Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
ID1609: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
ID1604: Esketamine for treating major depressive disorder in adults at imminent risk for suicide
ID1589: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
ID945: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
ID3787: Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis
ID1553: Cenobamate for focal onset seizures in epilepsy
ID3802: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
ID3734: Tralokinumab for treating moderate to severe atopic dermatitis
ID2722: Belimumab for treating lupus nephritis
ID1624: Berotralstat for preventing acute attacks of hereditary angioedema
ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE IDs
NICE IDs
04/09/2020
ID1549: Givosiran for treating acute hepatic porphyria
28/08/2020
ID1412: Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer
28/08/2020
ID1477: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
21/08/2020
ID1326: Volanesorsen for treating familial chylomicronaemia syndrome
21/08/2020
ID1304: Siponimod for treating secondary progressive multiple sclerosis
12/08/2020
ID1591: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
12/08/2020
ID1530: Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS)
09/07/2020
ID1468: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
09/07/2020
ID1586: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
09/07/2020
ID1510: Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable
08/07/2020
ID1473: Onasemnogene abeparvovec for treating spinal muscular atrophy type 1
08/07/2020
ID1294: Ozanimod for treating relapsing-remitting multiple sclerosis
08/07/2020
ID1534: Apalutamide for treating prostate cancer
08/07/2020
ID1420: Nintedanib for treating interstitial lung disease caused by systemic sclerosis
15/06/2020
ID901: Non-bisphosphonates for treating osteoporosis
10/06/2020
ID3754: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
04/05/2020
ID1583: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
28/04/2020
ID945: Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer
23/04/2020
ID1188: Erenumab for preventing migraine
23/04/2020
ID861: Metreleptin for treating lipodystrophy
1
2
3
4
5
6
7
Follow AWTTC: